The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
批准号:
10693227
负责人:
Julian Abrams
金额:
$81.24万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至 2027-08-31
关键词:
AccelerationAcidsAddressAdenocarcinomaAffectAgonistAreaBarrett EsophagusBile AcidsCell CountCellsCessation of lifeCollaborationsDataDeoxycholic AcidDevelopmentDistalDysplasiaEpithelial AttachmentEsophageal AdenocarcinomaEsophagogastric JunctionEsophagusFutureHigh Fat DietHumanImmuneInflammasomeInflammationInflammatoryKnock-outKnowledgeLGR5 geneMalignant NeoplasmsModelingModificationMolecularMusMyeloid CellsNatural Killer CellsNeoplasmsNuclearOrganoidsPatientsPopulationPrecancerous ConditionsProductionProliferatingProspective StudiesPublic HealthRegional CancerRisk FactorsRoleSamplingSeriesStomachStromal CellsTechniquesTranslatingValidationWorkantagonistcarcinogenesischemokineclinically significantcohortepithelial stem cellexperimental studygastroesophageal cancergut bacteriagut microbiomemicrobiomemicrobiome compositionmortalitymouse modelmultidisciplinaryneutrophilnew therapeutic targetnovelnovel strategiespreventprobiotic therapyprototyperational designreceptorsingle-cell RNA sequencingspatiotemporalstemstem cell fatestem cellsstomach cardia
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Stem and progenitor cells at the gastroesophageal junction (GEJ) have been identified as crucial to the
development of adenocarcinoma of the distal esophagus, gastroesophageal junction, and proximal stomach.
Combined, these cancers have over 20,000 new cases per year in the U.S., are associated high mortality, and
represent a major public health burden. Our group has identified both gastric cardia as well as GEJ transitional
basal stem cells as likely cells of origin for precancerous states in this region. However, defining the mechanisms
and effectors that drive GE junction stem cell fate and promote cancer development remains a critical gap in
knowledge. Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) represent the prototype for
neoplasia arising from GE junction stem cells. We have extensive preliminary data demonstrating that circulating
secondary bile acids derived from gut bacteria directly promote the development of BE and EAC, treating our
L2-IL1B mouse model of BE/EAC with deoxycholic acid (DCA) accelerates neoplasia, and treatment with
obeticholic acid, an agonist of nuclear bile acid receptor FXR (farnesoid X receptor), decreases proliferation,
GEJ stem cell numbers, and dysplasia. However, the exact mechanisms by which secondary bile acids impact
GEJ stem cells and the associated microenvironment have not been elucidated. We hypothesize that circulating
secondary bile acids produced by gut bacteria promote early cancer development via direct effects on GE
junction stem cells through FXR antagonism and by inducing pro-inflammatory microenvironment alterations.
Using highly novel techniques and approaches (including scRNA-Seq and CyTOF), we will perform a series of
experiments using mouse models, mouse and human organoids, and with validation of findings in a prospective
study of patients, to address the following specific aims: Aim 1. To determine the role of circulating secondary
bile acids in GEJ epithelial stem cell fate and early cancer promotion; Aim 2. To assess the effects of circulating
secondary bile acids on the GEJ epithelial stem cell microenvironment; Aim 3. To determine whether targeted
microbiome modification that regulates the circulating bile acid pool modifies GEJ cancer development. To
achieve these aims we will use our unique L2-IL1B mouse model with FXR knockout in stem cells (L2-
IL1B/Fxrfl/fl), allowing us to assess the effects of secondary bile acids on GEJ stem cells as well the L2-IL1B/Nlrpfl/fl
model to explore inflammasome activation in stem cells and assess for cross-talk with the microenvironment.
Ultimately, we will perform experiments treating with distinct consortia of highly characterized bacterial strains
to modulate the secondary bile acid producing capacity of the gut microbiome and determine the effects on
cancers arising from GE junction stem cells. Elucidation of the specific mechanisms by which secondary bile
acids interact with GEJ stem cells and modify the microenvironment to promote cancer development may lead
to the identification of novel therapeutic targets, including the potential for rationally designed probiotic therapy,
which would have a major public health impact.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Clinical Biospecimen and Research Core
-
批准号:10612956
-
项目类别:
-
资助金额:$22.75万
-
财政年份:2022
-
负责人:Julian Abrams
-
依托单位:
The Clinical Biospecimen and Research Core
-
批准号:10443135
-
项目类别:
-
资助金额:$23.82万
-
财政年份:2022
-
负责人:Julian Abrams
-
依托单位:
The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
-
批准号:10506039
-
项目类别:
-
资助金额:$84.51万
-
财政年份:2022
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microenvironment in Barrett's Esophagus
-
批准号:10607819
-
项目类别:
-
资助金额:$44.2万
-
财政年份:2022
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
-
批准号:10322389
-
项目类别:
-
资助金额:$51.08万
-
财政年份:2021
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
-
批准号:10747759
-
项目类别:
-
资助金额:$7.08万
-
财政年份:2021
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
-
批准号:10524194
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2021
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
-
批准号:10543870
-
项目类别:
-
资助金额:$52.39万
-
财政年份:2021
-
负责人:Julian Abrams
-
依托单位:
The Role of the Metaplastic Microenvironment in Barrett's Esophagus
-
批准号:10381174
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2021
-
负责人:Julian Abrams
-
依托单位:
The Oral Microbiome for the Detection of Barretts Esophagus
-
批准号:10647639
-
项目类别:
-
资助金额:$39.66万
-
财政年份:2019
-
负责人:Julian Abrams
-
依托单位:
Study of the Oral Microbiome to Address Racial Disparities in Esophageal Cancer
-
批准号:10249451
-
项目类别:
-
资助金额:$23.35万
-
财政年份:2019
-
负责人:Julian Abrams
-
依托单位:
The Oral Microbiome for the Detection of Barretts Esophagus
-
批准号:10397032
-
项目类别:
-
资助金额:$54.51万
-
财政年份:2019
-
负责人:Julian Abrams
-
依托单位:
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts Esophagus
-
批准号:8881844
-
项目类别:
-
资助金额:$8.12万
-
财政年份:2015
-
负责人:Julian Abrams
-
依托单位:
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts Esophagus
-
批准号:9050646
-
项目类别:
-
资助金额:$8.12万
-
财政年份:2015
-
负责人:Julian Abrams
-
依托单位:
Administrative Core
-
批准号:10183176
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2011
-
负责人:Julian Abrams
-
依托单位:
Project 3: Application of the Microbiome and Microenvironment to Novel Non Endoscopic Screening and Surveillance in Barrett's Esophagus
-
批准号:10183180
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2011
-
负责人:Julian Abrams
-
依托单位:
The Role of the Microenvironment in Barrett's Esophagus
-
批准号:10183175
-
项目类别:
-
资助金额:$114.54万
-
财政年份:2011
-
负责人:Julian Abrams
-
依托单位:
Risk factors for site-specific metastasis in esophageal cancer
-
批准号:7921303
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2009
-
负责人:Julian Abrams
-
依托单位:
Risk factors for site-specific metastasis in esophageal cancer
-
批准号:8308291
-
项目类别:
-
资助金额:$13.54万
-
财政年份:2008
-
负责人:Julian Abrams
-
依托单位:
Risk factors for site-specific metastasis in esophageal cancer
-
批准号:7694297
-
项目类别:
-
资助金额:$13.54万
-
财政年份:2008
-
负责人:Julian Abrams
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: